Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review

Phosphodiesterases (PDEs) have become a promising therapeutic target for various disorders. PDEs are a vast and diversified family of enzymes that degrade cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which have several biochemical and physiological functions. Phos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular biology reports 2024-12, Vol.51 (1), p.510-510, Article 510
Hauptverfasser:	Nongthombam, Pooja Devi, Haobam, Reena
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Animal Anatomy Animal Biochemistry Animals Apoptosis Biomedical and Life Sciences brain Cell death Central nervous system Chronic obstructive pulmonary disease Cyclic AMP Cyclic AMP - metabolism Cyclic GMP Cyclic GMP - metabolism Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Diethylstilbestrol - analogs & derivatives Dopamine Dopamine receptors Drug development Drugs Enzymes family FDA approval Histology Humans hydrolysis Kinases Life Sciences mammals Mammals - metabolism memory disorders Molecular biology Morphology Movement disorders Nervous system Neurodegeneration Neurodegenerative diseases Neurodegenerative Diseases - metabolism Neurological diseases Neurons Oxidative stress Parkinson Disease - drug therapy Parkinson's disease Phosphodiesterase Phosphodiesterase 4 Inhibitors - pharmacology Phosphodiesterase 4 Inhibitors - therapeutic use Phosphodiesterase IV Phosphorylation Proteins Review Signal transduction Therapeutic targets therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!